Posted by Michael Wonder on 25 Jun 2020
Consultation on CADTH’s drug reimbursement review procedures
25 June 2020 - CADTH is inviting stakeholder feedback on a revised procedure for its drug reimbursement review processes (i.e., pan-Canadian Oncology Drug Review, Common Drug Review, and Interim Plasma Protein Product Review).
This work has been undertaken to improve and align CADTH’s procedures, submission requirements, and internal processes.
The new proposed procedures have been established by adapting the best practices of each of the individual drug review processes (based on transparency, efficiency, timeliness, sustainability, and equity).
